Amodio Emanuele, Minutolo Giuseppa, Casuccio Alessandra, Costantino Claudio, Graziano Giorgio, Mazzucco Walter, Pieri Alessia, Vitale Francesco, Zarcone Maurizio, Restivo Vincenzo
Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90127 Palermo, Italy.
Unità Operativa Complessa di Epidemiologia Clinica con Registro Tumori, Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone", 90127 Palermo, Italy.
Vaccines (Basel). 2022 Feb 23;10(3):345. doi: 10.3390/vaccines10030345.
To date, Coronavirus disease (COVID-19) has caused high morbidity and mortality worldwide. To counteract the pandemic scenario, several vaccines against the etiological factor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were developed and tested. At the end of December 2020, BNT162b2 (Comirnaty, Pfizer-BioNTech) was the first and only authorized vaccine in Italy for selected categories, such as healthcare workers, fragile patients and people aged over 80 years old. To master our knowledge about BNT162b2 adverse reactions (ARs), an active surveillance system based on instant messaging was realized for voluntary participants who had been vaccinated at COVID-19 Vaccination Center of the Palermo University Hospital. Overall, 293 vaccinated persons were included in this study, which were more frequently healthcare workers (n = 207, 70.6% with a median age of 36 years, IQR = 29−55) followed by health professional students (n = 31, 10.6% with a median age of 27 years, IQR = 25−29), reporting 82.6% of at least one local or systemic AR. In details, the frequency of at least one local or systemic AR after the second dose of Comirnaty (n = 235, 80.2%) was statistically significant with higher value in comparison to the first one (n = 149, 50.9%; p < 0.001). However, local pain, swelling, joint pain and muscular pain after the second dose were the symptom causing a statistically significant working limitation. The youngest persons showed a higher risk to have either local or systemic ARs (aOR = 7.5, CI 95% = 2.9−18.9), while females had a higher risk of having systemic ARs (aOR = 1.8, CI 95% = 1.1−3.0). Despite the small sample examined, this active surveillance system by instant messaging seems to detect a higher ARs prevalence with respect to data obtained by the passive surveillance. Further studies could be required in order to optimize this clinical monitoring that could be considered an efficient and timely active surveillance.
迄今为止,冠状病毒病(COVID-19)已在全球范围内导致高发病率和高死亡率。为应对这一疫情形势,针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的致病因素研发并测试了多种疫苗。2020年12月底,BNT162b2(Comirnaty,辉瑞-生物科技公司)成为意大利首个也是唯一一种针对特定人群(如医护人员、脆弱患者和80岁以上人群)获批的疫苗。为掌握我们对BNT162b2不良反应(ARs)的了解,针对在巴勒莫大学医院COVID-19疫苗接种中心接种疫苗的自愿参与者,基于即时通讯实现了一个主动监测系统。总体而言,本研究纳入了293名接种疫苗者,其中医护人员更为常见(n = 207,70.6%,中位年龄36岁,四分位间距IQR = 29 - 55),其次是卫生专业学生(n = 31,10.6%,中位年龄27岁,IQR = 25 - 29),报告至少出现一种局部或全身ARs的比例为82.6%。详细而言,第二剂Comirnaty后至少出现一种局部或全身ARs的频率(n = 235,80.2%)与第一剂相比具有统计学显著性更高的值(n = 149,50.9%;p < 0.001)。然而,第二剂后的局部疼痛、肿胀、关节疼痛和肌肉疼痛是导致具有统计学显著性工作受限的症状。最年轻的人群出现局部或全身ARs的风险更高(调整后比值比aOR = 7.5,95%置信区间CI = 2.9 - 18.9),而女性出现全身ARs的风险更高(aOR = 1.8,95%CI = 1.1 - 3.0)。尽管所检查的样本量较小,但这种通过即时通讯进行的主动监测系统似乎比被动监测获得的数据检测到更高的ARs患病率。可能需要进一步研究以优化这种临床监测,其可被视为一种高效且及时的主动监测。